Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01931046 · ClinicalTrials.gov registry record · Phase 1

Use of Recombinant Adenovirus Therapy to Treat Localized Prostate Cancer

A Phase 1 study of Localized Prostate Cancer, sponsored by Momotaro-Gene.

Completed
Registry status
Phase 1
Development phase
28
Enrollment target
3
Study locations

NCT01931046 is a Phase 1 study of Localized Prostate Cancer that has completed, run by Momotaro-Gene. The registered enrollment target is 28 participants, below the 113-participant average among 6 other Localized Prostate Cancer trials with a reported enrollment target (75% lower). The trial reports 3 study locations across 3 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01931046, a Phase 1 study of Localized Prostate Cancer, has completed, sponsored by Momotaro-Gene.

COMPLETED
Registry status
Phase 1
Development phase
28 participants
Enrollment target
3
Study locations

Study Summary

The purpose of this study is to evaluate the safety and effectiveness of AD5-SGE-REIC/Dkk-3 in patients with localized prostate cancer.

Conditions Studied

Localized Prostate Cancer

Interventions

  • DRUG Ad5-SGE-REIC/Dkk3

Study Locations (3)

California

  • UCSD Moores Cancer Center - San Diego

Massachusetts

  • Brigham and Women's Hospital - Boston

Texas

  • The Methodist Hospital Research Institute - Houston

Trial Details

FieldValue
Enrollment Target 28 participants
Start Date 2013-10
Est. Completion 2020-03
Phase Phase 1

Sponsor

Momotaro-Gene

1 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT01931046

The ClinicalTrials.gov registry entry for NCT01931046 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 113-participant average among 6 other Localized Prostate Cancer trials with a reported enrollment target (75% lower). The listed sponsor is Momotaro-Gene, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Localized Prostate Cancer appearing as the primary indexed condition, and to 1 intervention - of which Ad5-SGE-REIC/Dkk3 is the first listed.

NCT01931046 reports 3 study locations spanning 3 distinct geographic areas - top geographies include California, Massachusetts, Texas.

Frequently Asked Questions

What is clinical trial NCT01931046 about?

NCT01931046 is a clinical study titled "Use of Recombinant Adenovirus Therapy to Treat Localized Prostate Cancer". The purpose of this study is to evaluate the safety and effectiveness of AD5-SGE-REIC/Dkk-3 in patients with localized prostate cancer.

What is the current status of trial NCT01931046?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2013-10. Estimated completion is 2020-03.

What conditions does trial NCT01931046 study?

This clinical trial studies the following conditions: Localized Prostate Cancer.

What interventions are being tested in trial NCT01931046?

The interventions under investigation include: Ad5-SGE-REIC/Dkk3 (DRUG).

Who is sponsoring clinical trial NCT01931046?

This trial is sponsored by Momotaro-Gene, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01931046 being conducted?

This trial has 3 study locations across California, Massachusetts, Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Localized Prostate Cancer

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Localized Prostate Cancer

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.